 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
9 News |  |
- Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
Dust to Dawn: A Case of Complicated Silicosis With Progressive Massive Pulmonary Fibrosis (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6328;
He ultimately underwent a surgical lung biopsy of his right middle lobe revealing multiple non-caseating anthrasilicotic granulomas that were negative for AFB, fungal stains and crystals on polarization...Despite being on maintenance prednisone in combination with maximal inhaler therapy for many years he has had symptomatic worsening...Our case demonstrates an infrequent but largely preventable disease with a poor prognosis. A thorough occupational history and chest imaging are diagnostic tools available for the diagnosis of silicosis with lung biopsy reserved for instances where a clinical diagnosis cannot be made.
- | Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
Preclinical, Journal: Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule. (Pubmed Central) - Mar 24, 2023
Similarly, ANTHRASIL was effective in cynomolgus monkeys (N = 16/group) when administered therapeutically after the onset of toxemia, with 6% survival in the IGIV control and a dose-related increase in survival of 36%, 43%, and 70% with 7.5, 15 or 30 U/kg doses of ANTHRASIL, respectively. These studies formed the basis for approval of ANTHRASIL by FDA under the Animal Rule.
- | Abthrax (raxibacumab) / Emergent Biosolutions, Anthrasil (AIGIV) / Emergent Biosolutions
Journal: Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins. (Pubmed Central) - Nov 15, 2022
These studies formed the basis for approval of ANTHRASIL by FDA under the Animal Rule. These data illustrate the relative therapeutic benefit of the 3 antitoxins and provide a rationale to prioritize their deployment.
- | Abthrax (raxibacumab) / Emergent Biosolutions, Anthrasil (AIGIV) / Emergent Biosolutions
Journal: Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins. (Pubmed Central) - Oct 25, 2022
These data illustrate the relative therapeutic benefit of the 3 antitoxins and provide a rationale to prioritize their deployment. These data illustrate the relative therapeutic benefit of the 3 antitoxins and provide a rationale to prioritize their deployment.
- || Abthrax (raxibacumab) / Emergent Biosolutions, Anthrasil (AIGIV) / Emergent Biosolutions
FDA event, Preclinical, Review, Journal: A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models. (Pubmed Central) - Jul 23, 2021
To provide a broader view of the potential effectiveness of these agents, this review examines the controlled preclinical experience either in antibiotic-treated B. anthracis models or in titrated hemodynamic-supported toxin-challenged canines. The strength and weaknesses of these preclinical experiences are discussed.
- | Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
Trial initiation date: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=10, Not yet recruiting, Sponsor: Emergent BioSolutions
The strength and weaknesses of these preclinical experiences are discussed. Initiation date: Aug 2018 --> Aug 2019
- || Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
Trial initiation date: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=100, Not yet recruiting, Sponsor: Emergent BioSolutions
Initiation date: Aug 2018 --> Aug 2019 Initiation date: Aug 2018 --> Aug 2019
- | Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
New trial: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL (clinicaltrials.gov) - Aug 6, 2018
P=N/A, N=10, Not yet recruiting, Sponsor: Emergent BioSolutions
- | Anthrasil (AIGIV) / Emergent Biosolutions, Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions
New trial: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL (clinicaltrials.gov) - Aug 6, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Emergent BioSolutions